Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue ...

The efficacy of drugs targeting the B-cell receptor signaling pathway has invigorated the enthusiasm to molecularly identify lymphoma subcategories that offer unique therapeutic opportunities.

This study systematically evaluates lymphoma ... I² = 44.2%, P = 0.127) (Supplementary Figure 3). When lymphomas were further classified by cell origin into B-cell and T-cell subtypes, no significant ...

Some antigenic stimuli may result in lymphoid proliferations that exhibit worrisome cytoarchitectural features but do not fulfill the full criteria for the diagnosis of lymphoma – that is ...

John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors. John Seymour, MBBS, FRACP, PhD, ...

Researchers with City of Hope and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR ...

high-grade BCL, transformed follicular lymphoma, and primary mediastinal LBCL. Health Canada first approved axi-cel in 2019 and tisa-cel in 2018. 2,3 Patients who received tisa-cel vs axi-cel were ...

District court judge David Faber rejected a call by prosecutors to force the distributors to pay $2.5 billion to fund an abatement plan to tackle an epidemic of deaths in Huntington and Cabell ...

2 In follicular lymphoma (FL), T-cell lymphoma and other hematologic and solid tumor studies, the agent was also well tolerated and had a differentiated safety profile. 1 This next-generation PI3Kδ ...